US FTC wants deals over generic entry involving payments to be curbed

5 February 2007

At a hearing of the US Senate Judiciary Committee, the Federal Trade Commission called for moves to prevent agreements between brand-name pharmaceutical companies and generic drugmakers to delay entry to the market of copy products, which has been possible under the provisions of the Hatch-Waxman legislation.

Committee chairman Patrick Leahy (Democrat, Vermont) put forward a bill at the hearing which would bar such deals. He said that these agreements between R&D and generics firms were tantamount to "collusion that limits consumer choices and keeps consumer prices artificially high," noting that "Congress never intended for brand-name drug companies to be able to pay off generic companies not to produce generic medicines."

Also testifying was Senator Arlen Specter (Republican, Pennsylvania), who said: "I do think there's a burden on people making these settlements to show why they are not anti-competitive," but added: "is it wise for the Congress to have a sweeping generalization that this is a per se violation?"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight